Table 2.
Laboratory findings of patients with COVID-19.
| Laboratory findings | Reference range | Mild (n = 21) | Moderate (n = 32) | p |
|---|---|---|---|---|
| Blood cell count | ||||
| White blood cell count, × 109/L | 3.5–9.5 | 5.1[4.05–5.2] | 5.2[3.82–6.25] | 0.894a |
| Neutrophil count, × 109/L | 1.8–6.3 | 2.11[1.69–3.23] | 3.12[1.88–4.33] | 0.068a |
| Neutrophil percentage, % | 40–75 | 43.9[37.8–54.2] | 57.3[48.25–64.7] | < 0.001a |
| Lymphocyte count, × 109/L | 1.1–3.2 | 2.25[1.62–2.85] | 1.65[1.21–2.10] | 0.010a |
| Lymphocyte percentage, % | 20–50 | 44.0[35.8–50.05] | 33.5[28.7–41.3] | 0.003a |
| NLR | 0.96[0.72–1.47] | 1.74[1.19–2.18] | < 0.001a | |
| Haemoglobin, g/L | 130–175 | 134[127.5–141.5] | 142.0[123.5–148.5] | 0.467a |
| Platelet count, × 109/L | 125–350 | 210[191.5–247.0] | 195.0[171.0–268] | 0.743a |
| Blood biochemistry | ||||
| Albumin, g/L | 40–50 | 44.4[43.25–46.55] | 43.15[41.52–44.97] | 0.072a |
| ALT, U/L | 9–50 | 14.2[10.5–20.45] | 18.1[6.51–12.75] | 0.029a |
| AST, U/L | 15–40 | 18.6[15.5–20.85] | 20.5[17.2–24.85] | 0.256a |
| Total bilirubin, mmol/L | 1.7–23 | 10.13[6.84–12.28] | 8.88[6.56–12.75] | 0.611a |
| Potassium, mmol/L | 3.5–5.3 | 4.20[4.12–4.72] | 4.47[4.13–4.95] | 0.317a |
| Sodium, mmol/L | 137–147 | 139.6[138.25–141.55] | 139.45[137.92–141.45] | 0.849a |
| Creatinine, μmol/L | 57–97 | 59.2[54.15–66.45] | 67.7[58.67–91.27] | 0.033a |
| LDH, U/L | 120–250 | 163.30[143.25–199.15] | 181.05[149.85–212.00] | 0.252a |
| cTnI, pg/mL | 0–40 | 0.1[0.1–0.1] | 0.1[0.1–0.1] | 0.418a |
| CKMB, U/L | 0–25 | 8.8[8.0–12.1] | 10.3[8.125–14.475] | 0.287a |
| Triglyceride, mmol/L | 0.6–1.7 | 0.68[0.54–1.01] | 0.88[0.776–1.02] | 0.052a |
| HDL, mmol/L | 1.04–1.56 | 2.19[1.73–2.83] | 1.45[1.13–2.42] | 0.008a |
| LDL, mmol/L | 1.03–3.38 | 2.21[1.65–2.42] | 2.19[1.73–2.83] | 0.335a |
| Total cholesterol, mmol/L | 3.1–5.2 | 3.94[3.45–4.42] | 3.80[3.25–4.61] | 0.920a |
| Glucose, mmol/L | 3.9–6.1 | 4.93[4.57–5.10] | 4.92[4.72–5.19] | 0.518a |
| Lactic acid, mmol/L | 0–2 | 2.1[1.8–2.3] | 2.1[1.7–2.4] | 0.802a |
| Coagulation | ||||
| PT, s | 9.1–12.1 | 13.6[13.35–14.15] | 13.6[13.12–14.00] | 0.964a |
| APTT, s | 25.4–38.4 | 39.8[35.5–42.55] | 39.15[37.00–45.22] | 0.418a |
| Fibrinogen, mg/dL | 2–4 | 2.62[2.495–3.015] | 3.48[2.88–3.87] | < 0.001a |
| D-dimer, mg/L | 0–231 | 220[220–300] | 270[220–402.5] | 0.127a |
| Infection-related | ||||
| PCT, ng/mL | 0.02–0.5 | 0.03[0.03–0.375] | 0.04[0.03–0.067] | 0.007a |
| CRP, mg/L | 0–6 | 0.39[0.165–1.335] | 3.41[0.865–17.24] | 0.010a |
| ESR, mm/h | 0–15 | 7.0[4.0–10.5] | 14.0[7.25–24.5] | 0.001a |
| Radiologic findings | ||||
| GGO | 28(87.5) | |||
| Consolidation | 14(43.8) | |||
| Lesion distribution | ||||
| Local | 17(53.1) | |||
| Multifocal | 15(46.9) | |||
| Unilateral | 22(68.8) | |||
| Bilateral | 10(31.3) | |||
| Total CT score | 2[1–3] | |||
Laboratory findings are presented as the median (25% quantile-75% quantile); radiologic findings are presented as the number of cases (percentage).
NLR neutrophil-to-lymphocyte ratio; ALT alanine aminotransferase; AST aspartate aminotransferase; LDH lactate dehydrogenase; cTnI cardiac troponin I; CKMB MB isoenzyme of creatine kinase; HDL high density lipoprotein; LDL low density lipoprotein; PT prothrombin time; APTT activated partial thromboplastin time; PCT procalcitonin; CRP C-reactive protein; ESR erythrocyte sedimentation rate; GGO ground glass opacity.
ap according to the Wilcoxon rank sum test.
All bold values indicate significant differences at the level of 0.05 for a highlight purpose.